



SurModics to Present at the Pacific Growth Equities Life Sciences Growth Conference

June 6, 2006

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 6, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the Pacific Growth Equities Life Sciences Growth Conference, held June 12-14 in San Francisco. The conference will feature presentations by more than 170 public and private companies.

Bruce Barclay, President and Chief Executive Officer and Phil Ankeny, Senior Vice President and Chief Financial Officer are scheduled to present an overview of the company and its growth strategies on Tuesday, June 13 at 6:30 p.m. (ET).

Interested parties may access a live webcast of the presentation by logging on to the Investors section of the SurModics website at www.surmodics.com. Investors are advised to visit the site at least 10 minutes before the scheduled presentation to register, download and install any necessary multimedia streaming software. The software plug-ins required for the live event can be either RealPlayer or Windows Media Player. The audio file of this webcast will be archived and available on the company's site for 30 days.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.

CONTACT: SurModics, Inc.
Phil Ankeny, 952-829-2700

SOURCE: SurModics, Inc.